Ribociclib as a Potential Multi-Target Inhibitor of Pro-Inflammatory Cytokines: An In Silico Investigation

Abstract

Ribociclib, a selective cyclin-dependent kinase (CDK) 4/6 inhibitor, is approved as a first-line therapy for HR-positive/HER2-negative advanced breast cancer. Emerging evidence suggests that Ribociclib may exert immunomodulatory effects. However, its role in cytokine regulation remains largely unexplored. This study presents a comprehensive in silico investigation of Ribociclibs interactions with eight key pro-inflammatory cytokines--IL-6, TNF-, IL-17A, IL-17F, IL-17A/F, IL-1{beta}, MCP-1, and IFN-{gamma}. Computational assessments included molecular docking, molecular dynamics (MD) simulations, MM-GBSA binding free energy calculations, principal component analysis (PCA), and dynamic cross-correlation matrix (DCCM) analyses. Molecular docking and MD simulations indicated strong and stable complex formation with TNF-, IL-6, MCP-1, IL-1{beta}, and IL-17A/F. MM-GBSA results further showed that Ribociclib formed the most stable complexes with IL-17A/F ({Delta}Gbind = -25.94 kcal/mol) and MCP-1 ({Delta}Gbind = -25.88 kcal/mol), comparable to binding with the CDK-6 ({Delta}Gbind = -36.23 kcal/mol) control protein. PCA and DCCM analyses further supported the stabilizing influence of Ribociclib on these cytokine conformations. Moderate interactions were observed with TNF-, IL-6, and IFN-{gamma}. Collectively, these findings suggest that Ribociclib may function as a multi-target inhibitor capable of modulating diverse inflammatory pathways, providing a computational foundation for its repurposing as a cost-effective anti-inflammatory therapeutic candidate.